piperazine has been researched along with Disease Models, Animal in 25 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epilepsy is a chronic neurological disorder which affects 65 million worldwide population and characterized by recurrent seizure in epileptic patients." | 5.48 | The anti-epileptogenic and cognition enhancing effect of novel 1-[4-(4-benzo [1, 3] dioxol-5-ylmethyl-piperazin-1-yl)-phenyl]-3-phenyl-urea (BPPU) in pentylenetetrazole induced chronic rat model of epilepsy. ( Kumari, S; Mishra, CB; Siraj, F; Tiwari, AK; Tiwari, M; Yadav, R, 2018) |
| "A series of piperazine ureas were designed, synthesized, and evaluated for their potential as novel orally efficacious fatty acid amide hydrolase (FAAH) inhibitors for the treatment of neuropathic and inflammatory pain." | 3.80 | Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors. ( Fujimoto, S; Imaeda, T; Kawamura, T; Kono, M; Kori, M; Kosugi, Y; Matsui, H; Matsumoto, T; Odani, T; Shimizu, Y; Shimojo, M, 2014) |
| "Piperazine ferulate (PF) has been reported to exert protective effects against the progression of DN." | 1.62 | Piperazine ferulate attenuates high glucose‑induced mesangial cell injury via the regulation of p66 ( Chen, Z; Deng, RR; Xiang, DX; Yang, XD; Yang, YY; Yao, LY, 2021) |
| "Hemarthrosis is the primary cause of hemophiliac arthropathy (HA)." | 1.51 | Novel Piperazino-Enaminones Decrease Pro-inflammatory Cytokines Following Hemarthrosis in a Hemophilia Mouse Model. ( Bill, A; Edafiogho, I; Ghoneim, O; Hua, B; Sun, J; Szollosi, D; Zhong, C; Zhuang, Y, 2019) |
| "Epilepsy is a chronic neurological disorder which affects 65 million worldwide population and characterized by recurrent seizure in epileptic patients." | 1.48 | The anti-epileptogenic and cognition enhancing effect of novel 1-[4-(4-benzo [1, 3] dioxol-5-ylmethyl-piperazin-1-yl)-phenyl]-3-phenyl-urea (BPPU) in pentylenetetrazole induced chronic rat model of epilepsy. ( Kumari, S; Mishra, CB; Siraj, F; Tiwari, AK; Tiwari, M; Yadav, R, 2018) |
| " Herein, we disclose the identification of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent, selective and orally bioavailable PI3Kδ inhibitors." | 1.46 | Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors. ( Bhide, RS; Bosnius, R; Cherney, RJ; Cornelius, LAM; Davies, P; Dhar, TGM; Goldstein, C; Gu, X; Neels, J; Poss, MA; Qin, LY; Ruan, Z; Ruepp, S; Sack, JS; Salter-Cid, L; Skala, S; Srivastava, AS; Stefanski, K; Susulic, V; Tino, JA; Weigelt, CA; Xie, J; Yang, X; Yarde-Chinn, M, 2017) |
| "BPPU also successfully inhibited seizures induced by 3-mercaptopropionic acid (3-MPA) and thiosemicarbazide (TSC) in mice thus, suggested that BPPU might influence GABA-ergic neurotransmission in the brain." | 1.43 | Pharmacological evaluation of novel 1-[4-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-phenyl]-3-phenyl-urea as potent anticonvulsant and antidepressant agent. ( Kumari, S; Mishra, CB; Tiwari, M, 2016) |
| " The lead compounds 5a, 6c, and 6e exhibited potent PAI-1 inhibitory activity and favorable oral bioavailability in the rodents." | 1.37 | Discovery of inhibitors of plasminogen activator inhibitor-1: structure-activity study of 5-nitro-2-phenoxybenzoic acid derivatives. ( Chakrabarti, G; Chaugule, B; Jain, M; Joshi, J; Joshi, N; Pandya, V; Parmar, B; Patel, H; Patel, J; Patel, P; Rath, A; Raviya, M; Sairam, KV; Shaikh, M; Soni, H, 2011) |
| "Indoleamine-induced myoclonus in guinea pigs is a specific model of brainstem 5-HT function that can be used to characterize the indoleamine systems initiating myoclonus." | 1.27 | 5-HT-mediated myoclonus in the guinea pig as a model of brainstem 5-HT and tryptamine receptor action. ( Jenner, P; Luscombe, G; Marsden, CD, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 15 (60.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, H | 1 |
| Cui, E | 1 |
| Li, J | 2 |
| Ma, X | 1 |
| Jiang, X | 1 |
| Du, S | 1 |
| Qian, S | 1 |
| Du, L | 1 |
| Li, Z | 1 |
| Meng, X | 1 |
| Ma, G | 1 |
| Liu, W | 1 |
| Li, W | 2 |
| Cai, Q | 1 |
| Wang, S | 1 |
| Huang, G | 1 |
| Zhang, Y | 3 |
| Jang, EH | 2 |
| Bae, HD | 2 |
| Jeon, Y | 2 |
| Shin, DH | 2 |
| Kang, S | 2 |
| Lee, K | 2 |
| Archana, A | 1 |
| Yang, YY | 2 |
| Deng, RR | 1 |
| Chen, Z | 1 |
| Yao, LY | 2 |
| Yang, XD | 1 |
| Xiang, DX | 2 |
| Rybka, S | 1 |
| Obniska, J | 1 |
| Żmudzki, P | 1 |
| Koczurkiewicz, P | 1 |
| Wójcik-Pszczoła, K | 1 |
| Pękala, E | 1 |
| Bryła, A | 1 |
| Rapacz, A | 1 |
| Wu, Y | 1 |
| Qi, H | 1 |
| Xiao, J | 1 |
| Gong, H | 1 |
| Xu, E | 1 |
| Li, S | 1 |
| Ma, D | 1 |
| Wang, Y | 1 |
| Shen, H | 1 |
| Stebbins, E | 1 |
| Jumani, RS | 1 |
| Klopfer, C | 1 |
| Barlow, J | 1 |
| Miller, P | 1 |
| Campbell, MA | 1 |
| Meyers, MJ | 1 |
| Griggs, DW | 1 |
| Huston, CD | 1 |
| Mishra, CB | 2 |
| Kumari, S | 3 |
| Siraj, F | 1 |
| Yadav, R | 1 |
| Tiwari, AK | 1 |
| Tiwari, M | 2 |
| Shi, LX | 1 |
| Li, JH | 1 |
| Xie, S | 1 |
| Li, X | 1 |
| Yu, H | 1 |
| Zhang, P | 1 |
| Wang, J | 1 |
| Wang, C | 1 |
| Xu, S | 1 |
| Wu, Z | 1 |
| Liu, J | 1 |
| Zhu, Z | 1 |
| Xu, J | 1 |
| Zhong, C | 1 |
| Szollosi, D | 1 |
| Sun, J | 1 |
| Hua, B | 1 |
| Ghoneim, O | 1 |
| Bill, A | 1 |
| Zhuang, Y | 1 |
| Edafiogho, I | 1 |
| Faist, J | 1 |
| Seebacher, W | 1 |
| Kaiser, M | 1 |
| Brun, R | 1 |
| Saf, R | 1 |
| Weis, R | 1 |
| Kono, M | 1 |
| Matsumoto, T | 1 |
| Imaeda, T | 1 |
| Kawamura, T | 1 |
| Fujimoto, S | 1 |
| Kosugi, Y | 1 |
| Odani, T | 1 |
| Shimizu, Y | 1 |
| Matsui, H | 1 |
| Shimojo, M | 1 |
| Kori, M | 1 |
| Zagórska, A | 1 |
| Kołaczkowski, M | 1 |
| Bucki, A | 1 |
| Siwek, A | 1 |
| Kazek, G | 1 |
| Satała, G | 1 |
| Bojarski, AJ | 1 |
| Partyka, A | 1 |
| Wesołowska, A | 1 |
| Pawłowski, M | 1 |
| Yin, Y | 1 |
| Wang, L | 1 |
| Liang, P | 1 |
| Li, M | 1 |
| Liu, X | 1 |
| Wu, L | 1 |
| Yang, H | 1 |
| Qin, LY | 1 |
| Ruan, Z | 1 |
| Cherney, RJ | 1 |
| Dhar, TGM | 1 |
| Neels, J | 1 |
| Weigelt, CA | 1 |
| Sack, JS | 1 |
| Srivastava, AS | 1 |
| Cornelius, LAM | 1 |
| Tino, JA | 1 |
| Stefanski, K | 1 |
| Gu, X | 1 |
| Xie, J | 1 |
| Susulic, V | 1 |
| Yang, X | 1 |
| Yarde-Chinn, M | 1 |
| Skala, S | 1 |
| Bosnius, R | 1 |
| Goldstein, C | 1 |
| Davies, P | 1 |
| Ruepp, S | 1 |
| Salter-Cid, L | 1 |
| Bhide, RS | 1 |
| Poss, MA | 1 |
| Gupta, S | 1 |
| Pandey, G | 1 |
| Rahuja, N | 1 |
| Srivastava, AK | 1 |
| Saxena, AK | 1 |
| Pandya, V | 1 |
| Jain, M | 1 |
| Chakrabarti, G | 1 |
| Soni, H | 1 |
| Parmar, B | 1 |
| Chaugule, B | 1 |
| Patel, J | 1 |
| Joshi, J | 1 |
| Joshi, N | 1 |
| Rath, A | 1 |
| Raviya, M | 1 |
| Shaikh, M | 1 |
| Sairam, KV | 1 |
| Patel, H | 1 |
| Patel, P | 1 |
| Nic Dhonnchadha, BA | 1 |
| Bourin, M | 1 |
| Hascoët, M | 1 |
| Cushion, MT | 1 |
| Walzer, PD | 1 |
| Ashbaugh, A | 1 |
| Rebholz, S | 1 |
| Brubaker, R | 1 |
| Vanden Eynde, JJ | 1 |
| Mayence, A | 1 |
| Huang, TL | 1 |
| Neustadt, BR | 1 |
| Hao, J | 1 |
| Lindo, N | 1 |
| Greenlee, WJ | 1 |
| Stamford, AW | 1 |
| Tulshian, D | 1 |
| Ongini, E | 1 |
| Hunter, J | 1 |
| Monopoli, A | 1 |
| Bertorelli, R | 1 |
| Foster, C | 1 |
| Arik, L | 1 |
| Lachowicz, J | 1 |
| Ng, K | 1 |
| Feng, KI | 1 |
| Komoto, T | 1 |
| Hirota, TK | 1 |
| Otsuka, M | 1 |
| Kotake, J | 1 |
| Hasegawa, S | 1 |
| Koya, H | 1 |
| Sato, S | 1 |
| Sakamoto, T | 1 |
| Luscombe, G | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
25 other studies available for piperazine and Disease Models, Animal
| Article | Year |
|---|---|
Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cyclooxygenase 2; Disease Models, Animal; Indazol | 2022 |
Increasing brain glucose metabolism by ligustrazine piperazine ameliorates cognitive deficits through PPARγ-dependent enhancement of mitophagy in APP/PS1 mice.
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; An | 2022 |
Meclizine, a piperazine-derivative antihistamine, binds to dimerized translationally controlled tumor protein and attenuates allergic reactions in a mouse model.
Topics: Animals; Biomarkers, Tumor; Disease Models, Animal; Histamine Antagonists; Hypersensitivity; Meclizi | 2023 |
Meclizine, a piperazine-derivative antihistamine, binds to dimerized translationally controlled tumor protein and attenuates allergic reactions in a mouse model.
Topics: Animals; Biomarkers, Tumor; Disease Models, Animal; Histamine Antagonists; Hypersensitivity; Meclizi | 2023 |
Meclizine, a piperazine-derivative antihistamine, binds to dimerized translationally controlled tumor protein and attenuates allergic reactions in a mouse model.
Topics: Animals; Biomarkers, Tumor; Disease Models, Animal; Histamine Antagonists; Hypersensitivity; Meclizi | 2023 |
Meclizine, a piperazine-derivative antihistamine, binds to dimerized translationally controlled tumor protein and attenuates allergic reactions in a mouse model.
Topics: Animals; Biomarkers, Tumor; Disease Models, Animal; Histamine Antagonists; Hypersensitivity; Meclizi | 2023 |
Synthesis of Novel Triazolyl/Oxadiazolyl/Thiadiazolyl-Piperazine as Potential Anticonvulsant Agents.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Female; Humans; Male; Mice; Oxadiazoles; Piperazin | 2021 |
Piperazine ferulate attenuates high glucose‑induced mesangial cell injury via the regulation of p66
Topics: Acute Kidney Injury; Animals; Collagen Type IV; Diabetic Nephropathies; Disease Models, Animal; Fibr | 2021 |
Synthesis and Determination of Lipophilicity, Anticonvulsant Activity, and Preliminary Safety of 3-Substituted and 3-Unsubstituted N-[(4-Arylpiperazin-1-yl)alkyl]pyrrolidine-2,5-dione Derivatives.
Topics: Animals; Anticonvulsants; Calcium Channels, L-Type; Cell Line, Tumor; Cell Survival; Disease Models, | 2017 |
A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma.
Topics: Animals; Asthma; Cell Migration Inhibition; Cell Survival; Disease Models, Animal; HEK293 Cells; Hum | 2017 |
Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model.
Topics: Administration, Oral; Animals; Animals, Newborn; Antinematodal Agents; Antiprotozoal Agents; Cattle; | 2018 |
The anti-epileptogenic and cognition enhancing effect of novel 1-[4-(4-benzo [1, 3] dioxol-5-ylmethyl-piperazin-1-yl)-phenyl]-3-phenyl-urea (BPPU) in pentylenetetrazole induced chronic rat model of epilepsy.
Topics: Animals; Cerebral Cortex; Chronic Disease; Cognition; Cognitive Dysfunction; Disease Models, Animal; | 2018 |
Piperazine ferulate ameliorates the development of diabetic nephropathy by regulating endothelial nitric oxide synthase.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Ani | 2019 |
Design, synthesis and biological evaluation of isochroman-4-one hybrids bearing piperazine moiety as antihypertensive agent candidates.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Hypertension; Molecular Structure; Piperaz | 2019 |
Novel Piperazino-Enaminones Decrease Pro-inflammatory Cytokines Following Hemarthrosis in a Hemophilia Mouse Model.
Topics: Animals; Cytokines; Disease Models, Animal; Hemarthrosis; Hemophilia A; Inflammation; Ketones; Mice; | 2019 |
Antiprotozoal activity of bicyclic diamines with a N-methylpiperazinyl group at the bridgehead atom.
Topics: Animals; Antiprotozoal Agents; Bridged Bicyclo Compounds; Cell Line; Cell Survival; Disease Models, | 2013 |
Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
Topics: Administration, Oral; Amidohydrolases; Analgesics; Animals; Brain; Disease Models, Animal; Drug Desi | 2014 |
Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Binding Sites; Disease Models, Animal; Models, | 2015 |
Pharmacological evaluation of novel 1-[4-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-phenyl]-3-phenyl-urea as potent anticonvulsant and antidepressant agent.
Topics: 3-Mercaptopropionic Acid; Animals; Anticonvulsants; Antidepressive Agents; Disease Models, Animal; E | 2016 |
Synthesis, Characterization, and Anti-Inflammatory Activities of Methyl Salicylate Derivatives Bearing Piperazine Moiety.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Cyclooxygenase 2; Cytokines; Disease Models, Animal; | 2016 |
Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors.
Topics: Amines; Animals; Autoimmune Diseases; Binding Sites; Class I Phosphatidylinositol 3-Kinases; Crystal | 2017 |
Design, synthesis and docking studies on phenoxy-3-piperazin-1-yl-propan-2-ol derivatives as protein tyrosine phosphatase 1B inhibitors.
Topics: Animals; Binding Sites; Catalytic Domain; Computer Simulation; Diabetes Mellitus, Experimental; Dise | 2010 |
Discovery of inhibitors of plasminogen activator inhibitor-1: structure-activity study of 5-nitro-2-phenoxybenzoic acid derivatives.
Topics: Administration, Oral; Animals; Benzoates; Biological Availability; Disease Models, Animal; Drug Desi | 2011 |
Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety.
Topics: Amphetamines; Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Animal; Dose-Response Relations | 2003 |
In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice.
Topics: Alkanes; Animals; Antifungal Agents; Benzamidines; Disease Models, Animal; Humans; Immunocompromised | 2006 |
Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Catalepsy; Disease Models, Animal; | 2007 |
New strong fibrates with piperidine moiety.
Topics: Animals; Disease Models, Animal; Hypercholesterolemia; Hypertriglyceridemia; Hypoglycemic Agents; Hy | 2000 |
5-HT-mediated myoclonus in the guinea pig as a model of brainstem 5-HT and tryptamine receptor action.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Brain; Carbidopa; Disease Models, Animal; Guinea Pig | 1986 |